milatuzumab

Ligand id: 8267

Name: milatuzumab

Immunopharmacology Comments
The first-in-class anti-CD74 monoclonal milatuzumab is being developed to treat hematological malignancies.
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
FDA and EMA orphan drug for CLL and multiple myeloma; in Phase 2 trial.